Evidence map›Paper›PMID 39091981›Full record

ArticleTherapeutic advances in infectious disease

Risk factors for treatment non-completion among patients with syphilis.

Abigail Clarkson-During, Ellen Almirol, Dylan Eller, Aniruddha Hazra, Kimberly A Stanford

Abstract read
In one paragraph

Article in Therapeutic advances in infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Abigail Clarkson-DuringSection of Emergency Medicine, The University of Chicago, Chicago, IL, USA.
Ellen AlmirolSection of Infectious Diseases and Global Health, The University of Chicago, Chicago, IL, USA.
Dylan EllerSection of Infectious Diseases and Global Health, The University of Chicago, Chicago, IL, USA.
Aniruddha HazraSection of Infectious Diseases and Global Health, The University of Chicago, Chicago, IL, USA.ORCID https://orcid.org/0000-0001-8557-4465
Kimberly A StanfordSection of Emergency Medicine, The University of Chicago, 5841 S. Maryland Avenue, MC 5068, Chicago, IL 60637, USA.ORCID https://orcid.org/0000-0002-7374-1323

Funding

Implementation of emergency department screening to impact rising syphilis rates in vulnerable populationsK23AI166277 · NIAID · UNIVERSITY OF CHICAGO · PI STANFORD, KIMBERLY · 2022 to 2025
$820k
NIAID NIH HHS K23 AI166277
6 · The paper itself

Abstract

Background: With recent increases in syphilis, there is growing interest in expanding screening; however, treatment rates have historically been low. Objectives: This study examines demographic and clinical factors that may contribute to non-completion of syphilis treatment. Design: This is a retrospective comparative cohort study of all patients with syphilis from January through November 2018 at an urban, tertiary care hospital. Methods: Demographics and clinical information were extracted from the electronic medical record. Descriptive statistics and odds ratios (ORs) were calculated. Results: Of 171 patients with syphilis, 89 (52.0%) completed treatment. Patients ages 40-49 were least likely to complete treatment (OR 0.14; 95% CI 0.03-0.72, Conclusion: A major gap in syphilis treatment still exists, which must be addressed to achieve optimal impact from syphilis screening programs.

Indexed as

emergency departmentHIV preventionsexually transmitted diseasesexually transmitted infectionsyphilistreatment

Identifiers

PMID39091981
PMCPMC11292680

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.